Fluticasone (generic), Flovent Newswire

Fluticasone (generic), Flovent Newswire

Comprehensive Real-Time News Feed for Fluticasone (generic), Flovent.

Results 1 - 20 of 56 in Fluticasone (generic), Flovent

  1. Comparing Adamis PharmaceuticalsRead the original story w/Photo

    Friday May 18 | AmericanBankingNews.com

    Adamis Pharmaceuticals and Aileron Therapeutics are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, earnings and profitability. Aileron Therapeutics has lower revenue, but higher earnings than Adamis Pharmaceuticals.

    Comment?

  2. What's Going Around: Hand, foot and mouth, allergies and asthmaRead the original story w/Photo

    Thursday May 17 | ABC 27

    This virus can start with a fever, sometimes as high as 105, for three to five days. Then, tiny blisters start to show up; typically around the mouth, on the hands and feet, and often in the diaper area.

    Comment?

  3. GSKs industry-leading respiratory research and scientific innovation showcased at ATS conferenceRead the original story

    Wednesday May 16 | PressReleasePoint

    GlaxoSmithKline plc will present extensive data from across its respiratory portfolio, pipeline and early phase research programmes at the American Thoracic Society conference in San Diego, USA, 19-23 May 2018. Data presented in 61 abstracts provide evidence on optimising the treatment and understanding of lung diseases.

    Comment?

  4. Advair ([fluticasone propionate + salmeterol]; GlaxoSmithKline) Drug Overview 2018: A Fixed-Dose Combination of an Inhaled Corticosteroid and a Long-Acting Beta 2 Agonist - ResearchAndMarkets.comRead the original story w/Photo

    Monday May 14 | The Galveston County Daily News

    Advair is a fixed-dose combination of an inhaled corticosteroid and a long-acting beta 2 agonist . The drug has anti-inflammatory and bronchodilatory effects on patients with asthma.

    Comment?

  5. GlaxoSmithKline/Innoviva's Breo Ellipta Drug Overview 2018 - ResearchAndMarkets.comRead the original story w/Photo

    Friday May 11 | The Galveston County Daily News

    Breo Ellipta is a combination of fluticasone furoate and vilanterol indicated for the treatment of asthma and chronic obstructive pulmonary disorder. Fluticasone furoate is an inhaled corticosteroid that activates the glucocorticoid response element and inhibits pro-inflammatory transcription factors such as NFB, and antigen-induced lung eosinophilia, thereby suppressing inflammation.

    Comment?

  6. Pulmonary Drug Delivery Devices Market Key Opportunities and Forecast Until 2019Read the original story w/Photo

    Wednesday May 2 | SBWire

    A newly compiled business intelligence study at the headquarters of Transparency Market Research has detected stiff competition in the global Pulmonary Drug Delivery Systems Market . And to stay ahead of the curve, key market players are resorting to technological advancements and are regularly introducing breakthrough products.

    Comment?

  7. Once-Daily Trelegy Ellipta Gains Expanded Indication in the US for...Read the original story w/Photo

    Monday Apr 23 | Drugs.com

    The new indication is for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema . It is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.

    Comment?

  8. Analysts See $-0.19 EPS for Adamis Pharmaceuticals (ADMP); Molina Healthcare Has 1.28 SentimentRead the original story w/Photo

    Saturday Apr 28 | Hill Country Times

    Analysts expect Adamis Pharmaceuticals Corporation to report $-0.19 EPS on May, 11.They anticipate $0.07 EPS change or 26.92% from last quarter's $-0.26 EPS. After having $-0.24 EPS previously, Adamis Pharmaceuticals Corporation's analysts see -20.83% EPS growth.

    Comment?

  9. Eosinophilic Esophagitis Market Overview and Regional Outlook Study 2017 - 2025Read the original story w/Photo

    Friday Apr 27 | SBWire

    Eosinophilic esophagitis is a chronic immunological disorder of the gastrointestinal system, in which a large number of eosinophils are present in the esophagus. The esophagus is a tube that carries food from the mouth to the stomach.

    Comment?

  10. Avoiding Errors With the Newer InhalersRead the original story

    Mar 27, 2018 | Pharmacy Times

    Several new devices for the administration of inhaled medications have been introduced. Some of the devices are used to administer newly marketed medications, while others contain previously available drugs in a different administration format.

    Comment?

  11. GSK announces positive EU approval for labelling update to Relvar Ellipta in patients with asthmaRead the original story

    Mar 8, 2018 | PressReleasePoint

    GlaxoSmithKline plc and Innoviva, Inc. today announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta , an inhaled corticosteroid / long-acting 2-agonist combination, in patients whose asthma is already adequately controlled on both an inhaled corticosteroid and long-acting 2-agonist. The Type II variation regulatory approval has been supported by data from a non-inferiority lung function study, which demonstrated that patients with adequately controlled asthma were able to switch to the once-daily FF/VI 100/25, from the twice-daily Seretide Accuhaler 250/50, without compromising their lung function.

    Comment?

  12. GlaxoSmithKline's Relvar Ellipta gets updated label in EURead the original story w/Photo

    Mar 8, 2018 | Live Charts

    GlaxoSmithKline and its partner Innoviva announced on Thursday that the European Commission has approved a label update for the use of once-daily Relvar Ellipta . The FTSE 100 drugmaker said Relvar Ellipta is an inhaled corticosteroid and long-acting I22-agonist combination, with the label update for patients whose asthma was already adequately controlled on both an inhaled corticosteroid and long-acting I22-agonist.

    Comment?

  13. GSK Announces Positive EU Approval for Labelling Update to Relvar Ellipta in Patients with AsthmaRead the original story

    Mar 8, 2018 | Customer Interaction Solutions

    GlaxoSmithKline plc and Innoviva, Inc. today announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta , an inhaled corticosteroid / long-acting Y2-agonist combination, in patients whose asthma is already adequately controlled on both an inhaled corticosteroid and long-acting Y2-agonist. The Type II variation regulatory approval has been supported by data from a non-inferiority lung function study, which demonstrated that patients with adequately controlled asthma were able to switch to the once-daily FF/VI 100/25, from the twice-daily Seretide Accuhaler 250/50, without compromising their lung function.

    Comment?

  14. Diphtheria Treatment Market Dynamics, Segments and Growing Demand 2018-2023Read the original story w/Photo

    Mar 2, 2018 | SBWire

    Bacterial infection affecting the mucous membrane of the throat and nose is known as diphtheria. The disease can easily spreads from one person to another.

    Comment?

  15. Long Acting Beta2-Agonists Drugs Market Segmentation Detailed Study with Forecast to 2025Read the original story w/Photo

    Feb 26, 2018 | SBWire

    Long-acting beta2-agonists are bronchodilators, a class of asthma medication, taken on a daily basis to relax the smooth muscle lining of bronchial tubes, the airways that carry air to the lungs. It allows the tubes to stay open for a longer period of time to help breathe easily.

    Comment?

  16. Forecast and Analysis on Preventive Asthma Drugs Market for Period 2017-2025Read the original story w/Photo

    Feb 23, 2018 | SBWire

    Asthma is a chronic inflammatory disease of the airways caused by recurrent attacks of breathlessness, bronchospasm, and reversible airflow obstruction. Asthma is a life threatening lung disease that hinders normal breathing.

    Comment?

  17. GSK announces CHMP positive opinion for labelling update to Relvar Ellipta in patients with asthmaRead the original story

    Jan 26, 2018 | PressReleasePoint

    GlaxoSmithKline plc and Innoviva, Inc. today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending a label update for the use of once-daily Relvar Ellipta , an inhaled corticosteroid / long-acting I22-agonist combination, in patients whose asthma is already adequately controlled on both an inhaled corticosteroid and long-acting I22-agonist. Jonathan Sweeting, SVP and Global Head of Respiratory Franchise GSK, said: "There are many asthma patients in Europe who, despite being adequately controlled on a twice-daily ICS/LABA, are still experiencing symptoms or problems with their asthma.

    Comment?

  18. GSK Announces CHMP Positive Opinion for Labelling Update to Relvar Ellipta in Patients with AsthmaRead the original story

    Jan 26, 2018 | Customer Interaction Solutions

    Jonathan Sweeting, SVP and Global Head of Respiratory Franchise GSK, said: "There are many asthma patients in Europe who, despite being adequately controlled on a twice-daily ICS/LABA, are still experiencing symptoms or problems with their asthma. "We are very excited about achieving this CHMP positive opinion which, if approved, provides an additional option for physicians, who can prescribe once-daily Relvar Ellipta for their asthma patients."

    Comment?

  19. Eosinophilic Esophagitis Market Trends & Opportunities with Forecast Up to 2025Read the original story w/Photo

    Jan 23, 2018 | SBWire

    Eosinophilic esophagitis is a chronic immunological disorder of the gastrointestinal system, in which a large number of eosinophils are present in the esophagus. The esophagus is a tube that carries food from the mouth to the stomach.

    Comment?

  20. Long Acting Beta2-Agonists Drugs Market Latest Trends and Forecast Analysis Up to 2025Read the original story w/Photo

    Jan 19, 2018 | SBWire

    Long-acting beta2-agonists are bronchodilators, a class of asthma medication, taken on a daily basis to relax the smooth muscle lining of bronchial tubes, the airways that carry air to the lungs. It allows the tubes to stay open for a longer period of time to help breathe easily.

    Comment?